• Geoffrey T Gibney, Louis M Weiner, and Michael B Atkins.
• Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington DC, USA. Electronic address: geoffrey.t.gibney@gunet.georgetown.edu.
• Lancet Oncol. 2016 Dec 1; 17 (12): e542e551e542-e551.

AbstractThe clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.Copyright © 2016 Elsevier Ltd. All rights reserved.

17 keywords...

hide…